Efficacy of sublingual allergen immunotherapy in asthma with allergic rhinitis

Efficacy of sublingual allergen immunotherapy in asthma with allergic rhinitis - Efficacy of sublingual allergen immunotherapy in asthma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022390

Enrollment

100

Registered

2016-05-20

Start date

2016-03-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma with allergic rhinitis

Interventions

Allergen immunotherapy group (1 tablet/day over 3 year) Control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Asthma with allergic rhinitis

Exclusion criteria

Exclusion criteria: 1.Patients who have severe allergic reactions to this tablet. 2.Malignancy. 3.Strong severe ashma patients. 4.Pregnancy.

Design outcomes

Primary

Measure	Time frame
Serum periostin(after treatment at weeks 24,48,96,144)	—

Secondary

Measure	Time frame
Pulmonary function FeNO airway wall thckness QoL	—

Countries

Japan

Contacts

Public ContactMakoto Hoshino

Atami Hospital, International University of Health and Welfare Division of Clinical Allergy

hoshino@iuhw.ac.jp0557-81-9171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026